Report of Foreign Issuer (6-k)
January 07 2019 - 7:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of January 2019
Commission File Number:
001-37452
CELYAD SA
(Translation
of registrants name into English)
Rue Edouard
Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F.
Form
20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
Celyad SA
On January 7, 2019, Celyad S.A. (the
Company
) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
The Company will be conducting meetings with investors attending the 37th Annual J.P. Morgan Healthcare Conference in
San Francisco beginning on January 7, 2019. As part of these meetings, the Company will deliver the slide presentation furnished to this report as Exhibit 99.2 and which is incorporated herein by reference.
The information in this report included as Exhibit 99.1 and Exhibit 99.2 and incorporated herein by reference shall not be deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act
or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to this report.
EXHIBITS
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press release issued by the registrant on January 7, 2019
|
|
|
99.2
|
|
Investor presentation furnished by Celyad S.A.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CELYAD SA
|
|
|
|
|
Date: January 7, 2019
|
|
|
|
By:
|
|
/s/ Filippo Petti
|
|
|
|
|
|
|
Filippo Petti
Chief Financial
Officer
|
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Apr 2023 to Apr 2024